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Abstract: Glioblastoma is an aggressive brain tumor with a low survival rate. Understanding tumor
behavior by predicting prognosis outcomes is a crucial factor in deciding a proper treatment plan. In
this paper, an automatic overall survival time prediction system (OST) for glioblastoma patients is
developed on the basis of radiomic features and machine learning (ML). This system is designed to
predict prognosis outcomes by classifying a glioblastoma patient into one of three survival groups:
short-term, mid-term, and long-term. To develop the prediction system, a medical dataset based
on imaging information from magnetic resonance imaging (MRI) and non-imaging information
is used. A novel radiomic feature extraction method is proposed and developed on the basis of
volumetric and location information of brain tumor subregions extracted from MRI scans. This
method is based on calculating the volumetric features from two brain sub-volumes obtained from
the whole brain volume in MRI images using brain sectional planes (sagittal, coronal, and horizontal).
Many experiments are conducted on the basis of various ML methods and combinations of feature
extraction methods to develop the best OST system. In addition, the feature fusions of both radiomic
and non-imaging features are examined to improve the accuracy of the prediction system. The best
performance was achieved by the neural network and feature fusions.
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Gliomas are common brain tumors that start in the glial cells, which are gluey supportive cells that surround nerve cells in the brain, and they represent 80% of primary malignant
brain tumors [1,2]. These tumors can affect brain function and be life-threating depending
on growth rate, size, and location. Glioma tumors are classified into two types according to
their aggressiveness: low-grade glioma (LGG) and high-grade glioma (HGG) [3,4]. Some
LGGs are benign tumors [5], while HGGs are malignant tumors [6]. Malignant tumors are
aggressive tumors that contain cancerous cells and are life-threatening. These tumors have
irregular boundaries with a high growth rate. Glioblastoma multiforme (GBM) tumors are
the most common type of HGG [3,7,8], classified as a grade IV glioma, the most aggressive
grade of brain tumors, by the World Health Organization (WHO) [2,9,10]. These tumors
represent 50% of gliomas [2,11,12]. Furthermore, 90% of GBMs are primary tumors [9,13].
Unfortunately, patients with GBM tumors have a very poor survival rate and prognosis
outcome. Several risk factors are recognized to increase the chance of developing brain
tumors. Some of these factors can be controlled and are related to the patient’s lifestyle
behaviors, such as smoking, dietary habits, and alcohol intake. However, other factors
cannot be controlled such as age, family history, and genetics. In addition, some diagnosis
methods that are based on ionizing radiation, such as prenatal diagnostic X-ray exposure,
increase the risk of developing childhood brain tumors [14,15]. According to the American
Cancer Society (ACS), the GBM patient’s age is associated with the survival rate, which
is better for young people than for old people [16–18]. For example, the 5 year relative
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survival rate is 22% for patients aged 20–44 years, whereas it is 6% for patients aged
55–64 years [17]. To diagnose glioma brain tumors accurately, different tests are required,
such as neurological exams, imaging tests, and biopsy tests [19–21]. Due to the superior soft
tissue contrast of magnetic resonance imaging (MRI) scans, which allow for better visualization of the complexity and the heterogeneity of tumor regions, it is recognized as a gold
imaging method to identify and localize brain tumors [20,22]. Glioma brain tumors have a
variable prognosis and various heterogeneous histological subregions, which are reflected
in their imaging phenotype [23–25]. In general, the common brain tumor subregions are
peritumoral edema, necrosis, cyst, and enhancement tumor [26]. Different structural MRI
modalities, such as T1-weighted (T1) scans, T2-weighted (T2) scans, contrast-enhanced
T1-weighted (cT1) scans, and fluid-attenuated inversion recovery (FLAIR) scans, can be
used to visualize different brain tumor subregions [22]. For example, T2 and FLAIR scans
visualize the peritumoral edema as a bright region [26,27]. Necrosis is identified as a bright
region in the T2 scan but a dark region in the T1 scan, with an irregular enhancing border
in the cT1 scan [26]. The cyst is recognized as a dark, rounded region in the T1 scan and is a
very bright region in the T2 scan [26]. Another study used cT1 scans to justify the existence
of the cystic component [28]. However, the existence of a cyst is rare as GBM is commonly
developed as a unilateral solid tumor [28]. The enhancement tumor (ET) region is defined
as a bright region surrounding the cystic/necrotic components, and the Multimodal Brain
Tumor Segmentation challenge (BraTS) recognized it by comparing T1 and cT1 scans [29].
The tumor core (TC), which includes both the ET region and cystic/necrotic components,
can be visible in the T2 scan, while the whole tumor (WT) region is visible in the FLAIR
scan [29].
To improve the poor prognosis of GBM, various clinical investigations studied the
connection among appearance, size, and location of GBM tumor subregions in relation
to the poor survival rate [30–32]. Tissue death in cancers is called necrosis, and it was
found that the existence of a necrotic tumor is associated with a poor survival rate [33].
Peritumoral edema can be defined as a characteristic feature of malignant glioma regarding
the extent of neovascularization and vascular endothelial growth factor (VEGF) expression [30,34]. Angiogenic and vascular permeability factors associated with infiltrating
tumors are identified as reasons for edema development [35,36], which is often presented
in GBM and associated with poor prognosis [27,37]. Wu et al. found a shorter survival rate
in glioblastoma patients due to the existence of both edema and necrosis [26]. Qin et al.
summarized that the surgical treatment of edema delayed postoperative recurrence and
relapse rates [27]. In addition, the survival rate of glioma patients is associated positively
with the appearance of cystic tumor components [32].
Due to the power of ML methods in developing accurate prediction systems that
can identify complex and nonlinear patterns in different data types, they have recently
been used to improve the healthcare systems in enhancing the diagnosis process and drug
discovery [38,39], as well as in deciding a suitable treatment plan [40–43]. The term ML
represents all traditional ML methods, such as the support vector machine (SVM), neural
network (NN), trees, random forest (RF), and K-nearest neighbor (KNN), including deep
learning (DL) methods, which are just NNs with a very deep structure. Recently, most
researchers have used the term “ML” for traditional ML methods and “DL” for deep neural
network methods. Various studies have involved prediction methods based on ML/DL
and medical data to predict prognosis outcomes. Different types of medical images were
used to develop an OST prediction system for different cancers [44–49]. For example, MRI
images were used for glioma brain tumors and HGG tumors [45,48], while CT scans were
used for pancreatic ductal adenocarcinoma, head and neck squamous cell carcinoma, lung,
and gallbladder cancers [44,46,47,49].
To develop state-of-the-art OST prediction methods for GBM patients, the BraTS challenge provided well-processed medical data based on medical imaging information (MRI)
and non-imaging information [23,29]. Numerous methods based on ML and radiomic
features were proposed and examined [50–55], and details about the top ranked methods
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are listed in Table 1 for BraTS 2018 and 2019. The BraTS validation and test datasets
are unlabeled data as described in [56]. The validation data were provided to evaluate
developed prediction models and to choose the best model for the test phase. The test
data were provided to test and evaluate the final (best) prediction model. The participant
should conduct predictions and submit the results to the BraTS challenge for evaluation.
From Table 1, it is obvious that tumor size, which represents the volume information of
tumor/tumor subregions, is an important radiomic feature in developing an automatic
prediction model for GBM patients.
Table 1. State-of-the-art overall survival time prediction methods for glioblastoma patients using BraTS 2018 and 2019
datasets, where RS refers to the resection status and Acc refers to the accuracy.
Study (Rank-Year)

Features

ML Model

Validation Acc

Test Acc

Feng et al. (1st 2018) [50]

Radiomics (size, shape) + (age, RS)

Linear regression
model

32.1%

-

Puybareau et al.
(2nd 2018) [51]

Radiomics (size, location) + age

Random forest

54%

61%

Baid et al. (3rd 2018) [52]

Radiomics (shape, statistical,
texture) + age

Neural network

57.1%

55.8%

Agravat et al.
(1st 2019) [53]

Radiomics (shape, statistical
texture) + age

Random forest
regressor

58.6%

57.9%

Wang et al. (2nd 2019) [54]

Radiomics (shape, location, texture
features) + invasiveness + (age, RS)

Random forest,
epsilon-support vector
regression

59%

-

Wang et al. (3rd 2019) [55]

Radiomics (size, shape) + age

Fully connected neural
network with two
hidden layers

44.8%

55.1%

In this paper, we propose a novel method to extract volumetric and location information of GBM tumors, as well as the tumor subregions. Our proposed feature extraction
method is based on calculating the volume of the GBM brain tumor and the tumor subregions in different brain function regions. To our knowledge, there is no automatic
software/program that identifies each brain functional region (i.e., lobe) in structural
MRI scans. Therefore, an alternative method is proposed to divide a brain volume into
two sub-volumes (regions) using the brain section planes (mid-sagittal, mid-coronal, and
mid-horizontal). Then, the volumes of the tumor region and subregions are calculated
in each brain sub-volume. As the three brain section planes are used, three approaches
are proposed to extract three different sets of radiomic features to train an ML prediction
system. The BraTS 2019 dataset was used to develop our prediction system based on a
classification process, which classifies a GBM patient into one of three survival groups:
short-term, mid-term, and long-term.
The remainder of this paper is organized as follows: Section 2 presents the methods
and materials used to develop and evaluate the OST prediction system for GBM patients;
Section 3 lists and illustrates experiments and results that were used to test and evaluate
the proposed prediction system; Section 4 discusses the achieved results and compares
them with previous studies; Section 5 concludes this work and highlights future work to
improve the performance of the proposed prediction system.
2. Materials and Methods
In this paper, medical data based on medical imaging information and non-imaging
information were used to develop an accurate OST prediction system for GBM patients.
Therefore, traditional ML methods were used to train the OST prediction system. Most
medical images are 3D and have a big size in terms of the number of voxels. Sometimes
they are not suitable to train reliable prediction models based on traditional ML methods
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age is included directly in the feature vector. Two values are used to implement the
2.3. Modeling OST Classifier
tion status
feature: “1” is for GTR, and “0” is for both STR and unknown resection

To develop an automatic prediction system that classifies a GBM patient into one of
the three survival groups (short-term, mid-term, long-term), ML algorithms were used. The
2.3. Modeling
Classifier
short-term OST
survivor
group represents patients with a survival time of less than 10 months;
the
mid-term
survivor
group represents
patients
with a survival
time of 10–15
months;
the into
To develop an automatic
prediction
system
that classifies
a GBM
patient
long-term survivor group represents patients with a survival time of more than 15 months.
the threeTosurvival
groups (short-term, mid-term, long-term), ML algorithms were
develop an accurate automatic prediction model based on the classification task, a
The short-term
survivor
groupwhich
represents
modeling process
was required,
includedpatients
three mainwith
steps,aassurvival
shown in time
Figureof
1: less th
model
training,
model survivor
validation, and
model
testing. Therefore,
thewith
dataseta was
dividedtime of
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the
mid-term
group
represents
patients
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into
three
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training,
validation,
and
testing.
The
training
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was
the
largest
months; the long-term survivor group represents patients with a survivalintime o
size compared to the validation and test dataset, and it was used to train the model by
than implementing
15 months. ML algorithms to predict the outcomes (overall survival time) on the basis
Tothe
develop
an accurate
automatic
prediction
model
on the
classificatio
of
labeled target.
The validation
data were
used to tune
modelbased
parameters,
checking
for any model
bias/overfitting
problems.
testing dataset
were unseen
used in Fig
a modeling
process
was required,
whichThe
included
three main
steps, data
as shown
to evaluate and test the performance of a prediction model. In the model training step,
model training, model validation, and model testing. Therefore, the dataset was d
the extracted features from the training dataset with labels (three survival time groups)
into three
sets:with
training,
validation,
testing. The
training
dataset was
the largest
were used
ML algorithms
to trainand
the prediction
model
using a supervised
learning
approach.
To produce
a reliable
prediction
model,
tuning
required
in
compared
to the
validation
and test
dataset,
andparameter
it was used
towas
train
the model
by
the
model
validation
step
using
the
validation
dataset.
This
step
is
very
important
to
menting ML algorithms to predict the outcomes (overall survival time) on the basis
avoid model overfitting, as well as to check for any model bias problems. To justify the
labeled
target. The validation data were used to tune model parameters, checking f
model’s performance, the model was examined using the testing dataset. To produce a
model
bias/overfitting
problems.
The
testing dataset
were
unseen
data used to ev
reliable
ML prediction model,
the k-fold
cross-validation
method
was used
to avoid/reduce
model
overfitting.
and test
the
performance of a prediction model. In the model training step, the ext

features
from the training dataset with labels (three survival time groups) were use
3. Results
ML algorithms
tothe
train
model
using
supervised
learning
To develop
best the
OSTprediction
prediction model
based
on theaproposed
radiomic
featuresapproa
produce
a reliable
model,
parameter
tuning
wasbelow.
required in the model v
and ML
methods,prediction
three experiments
were
conducted, as
described
the first
experiment,
three
sets of radiomic
features
(mid-sagittal,
mid-coronal,
and
tion stepInusing
the
validation
dataset.
This step
is very
important
to avoid
model o
mid-horizontal were extracted from the BraTS 2019 training dataset to train an ML model
ting, as well as to check for any model bias problems. To justify the model’s perform
using a three-class classification process. Six ML methods (NN, SVM, tree, naïve Bayes,
the model
was examined
usingwere
theused
testing
dataset.
a reliable
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linear discriminant,
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to develop
the To
OSTproduce
classification
model for
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of the
threecross-validation
sets of the radiomic method
features. Several
configurations
were implemented
model,
k-fold
was used
to avoid/reduce
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3.

to produce the best prediction model for each ML method. The best models are listed
in Tables 3–5 for the mid-sagittal approach, mid-coronal approach, and mid-horizontal
Results
approach, respectively. The results show that the best performance was achieved by NN
for
three sets
of the
radiomic
features.
Tothe
develop
the
best
OST prediction
model based on the proposed radiomic

fe

and ML methods, three experiments were conducted, as described below.
In the first experiment, three sets of radiomic features (mid-sagittal, mid-coron
mid-horizontal were extracted from the BraTS 2019 training dataset to train an ML
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Table 3. Performance of the best OST prediction systems, using radiomic features based on midsagittal plane and various ML methods.
No. of Features

ML Method

Overall Accuracy

12

NN (hidden nodes = 150)
SVM (fine Gaussian)
KNN (weighted)
Naïve Bayes (Gaussian)
Linear discriminant
Tree (ensemble)

53.3%
44.3%
49.5%
43.9%
54.8%
46%

Table 4. Performance of the best OST prediction systems, using radiomic features based on midcoronal plane and various ML methods.
No. of Features

ML Method

Overall Accuracy

12

NN (hidden nodes = 50)
SVM (fine Gaussian)
KNN (coarse)
Naïve Bayes (Gaussian)
Linear discriminant
Tree (fine)

53.3%
45.3%
44.3%
42.5%
43.4%
39.2%

Table 5. Performance of the best OST prediction systems, using radiomic features based on midhorizontal plane and various ML methods.
No. of Features

ML Method

Overall Accuracy

12

NN (hidden nodes = 40)
SVM (fine Gaussian)
KNN (weighted)
Naïve Bayes (Gaussian)
Linear discriminant
Tree (boosted)

53.2%
48.6%
49.5%
39.6%
42%
42%

In the second experiment, the survival rate of GBM patients was associated with
the patients’ age, which is better for young people than for old people according to the
ACS [16–18]. Thus, the age factor was used as a non-imaging feature and was combined
with the radiomic features to improve the performance of the OST classification model
based on NN. A simple NN architecture was used to develop the prediction system,
consisting of an input layer, a hidden layer, and an output layer, as shown in Figure 6.
The size of the input layer was equal to the size of the feature vector. The hidden layer
consisted of a number of nodes. The output layer consisted of three output nodes as the
OST prediction system had three classification groups (short-term, mid-term, and longterm). We used the hyperbolic tangent sigmoid activation function (tanh) in the hidden
layer and the softmax activation function in the classification layer. Several configurations
were implemented to tune the size of the hidden layer (i.e., the number of NN nodes) for
the three sets of features. The best prediction models based on the three approaches are
listed in Table 6.
For the third experiment, it was found that the surgical treatment improved the
survival time for GBM patients [27]; thus, the resection status was added to the three sets
of the radiomic features, in addition to the age feature, to improve the performance of
the prediction system. Then, the new feature vectors were used to train the NN classifier.
Several configurations were implemented to tune the size of the hidden layer, as well as
develop the best prediction rate. Table 7 displays the best developed OST models based
on feature fusions (radiomic features and non-imaging features) for the three approaches
(mid-sagittal, mid-coronal, and mid-horizontal). For better understanding the performance
of the developed classification models in Table 7, confusion matrices and receiver operating
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the NN classifier. As the survival time is better for patients after surgical treatment [27],
increased when feature fusions of radiomic and non-imaging features were used to train
we expected better improvements in the system performance of Experiment 3 (Table 7)

the NN classifier. As the survival time is better for patients after surgical treatment [27],
we expected better improvements in the system performance of Experiment 3 (Table 7)
compared to Experiment 2 (Table 6). We believe that these slight improvements of accuracy
in the validation and testing datasets of Experiment 3 were due to the unknown resection
status for more than half of the samples of the data, which provided unclear descriptions
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for this feature. We believe that, if we have complete information about the resection status
for all of the patients, the test accuracy will increase in Experiment 3.
In addition, according to the results in Figure 7 (confusion matrices and ROCs in
the test data), type II errors number of false negatives (FNs)) were more common than
type I errors (number of false positive (FPs)) in the mid-term survival (Class 2), but less
common than type I errors in the long-term survival (Class 3) for the three approaches
of the radiomic features. Type II errors were also more common than type I errors in the
short-term survival (Class 1) for both the mid-sagittal and mid-coronal radiomic feature
approaches, but they were similar in number to type I errors in the mid-horizontal radiomic
feature approach. Moreover, Class 2 had the worst area under the curve (AUC) compared
to Class 1 and Class 3 for the three radiomic feature approaches. Thus, the accuracy of
Class 2 was the worst compared to Class 1 and Class 3. There are three reasonable reasons
for the reduction in accuracy of Class 2. First, the data were unbalanced, as shown in
Table 2, whereby the number of patients (i.e., samples) of Class 2 was approximately 30%
lower than the number of the patients in Class 1 and Class 3. This could have affected the
quality of the developed descriptors, as well as the prediction rate of Class 2. Second, the
time period range of Class 2 in months is 6 months (10 months to 15 months) which is
small compared to Class 1 (9 months) and Class 3 (more than 15 months, up to 60 months).
This might have produced a model with descriptors that contain information from Class 1
and Class 3, which definitely affected the accuracy of Class 2. Third, the survival time of
300 days (10 months) was used to separate Class 2 and Class 1, whereas the survival time
of 450 days (15 months) was used to separate Class 2 and Class 3. Thus, Class 2 has two
critical zones (one with Class 1 (day 300) and another one with Class 3 (day 450), whereas
Class 1 and Class 3 have only one critical zone (day 299) and (day 451) for Class 1 and
Class 3, respectively. This allowed Class 2 to have samples containing features of Class 1
and Class 3. To clarify this point, Figure 3b shows there were six patients with an overall
survival time of 9 months (short-term), and two of these patients had a survival time of
296 days. Eight patients had an overall survival time of 16 months (long-term), and one of
these patients had a survival time of 453 days. This means that, within more or less a few
days, these patients would be considered Class 2. Furthermore, one of the patients with a
survival time of 10 months (mid-term) had a survival time of 300 days, and two patients
with a survival time of 15 months had a survival time of 448 days (mid-term). Thus, these
patients were in a critical time interval, which makes them likely to have descriptors from
other classes. We believe that increasing size of the training dataset and/or using balanced
data can decrease the occurrence of type I errors and type II errors, as well as improve the
performance of the prediction system.
Moreover, the test accuracy of the OST prediction model developed in this paper is
better than the test accuracy of our previous work, which was based on radiomic features
from eight and four brain sub-volumes and shape features [57]. In addition, the results
of our prediction system are competitive compared with the top achievements in BraTS
2018–2019 [50–55], as their best accuracy in the unseen dataset did not exceed 62%, as
shown in Table 1.
5. Conclusions and Future Work
Our feature extraction method based on brain functional regions is suitable to develop
an automatic OST prediction system for glioblastoma patients based on traditional ML
methods, even when a small dataset is used. In addition, the NN showed the ability to
develop the best prediction models compared to other ML methods, potentially due to
the ability of the NN architecture to render nonlinearity and complexity in a dataset. We
planned on testing and evaluating our proposed method in BraTS 2021, but they did not
release a survival task this year (2021). To improve the performance of the developed OST
prediction system, the following strategies can be used: increasing the size of the dataset,
as well as using a balanced dataset by either collecting new samples or using proper
data augmentation methods, using completed information of the resection status feature
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for all patients in the dataset, combining the features of the three proposed approaches,
combining other types of radiomic features (shape, texture) with volumetric and location
features, and using a multimodal dataset, which contains other types of data that relate
to developing aggressive brain tumors, such as genomic data. In addition, as the brain
functionality regions (lobes) are responsible for controlling specific organs and functions
in a human body, we believe extracting the proposed volumetric features from the brain
lobes will improve the performance of the OST prediction system. Moreover, the possibility
of developing an accurate OST regression model instead of a classification model can be
explored to solve the unbalanced data problem.
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Appendix A
The type and order of radiomic features extracted based on the three approaches of
the proposed method are listed in Tables A1–A3.
Table A1. Volumetric features extracted from mid-sagittal plane approach.
Feature Type

Description

Vwb
Vwt
VtL
VtR
VbL
VbR
VEDL
VEDR
VETL
VETR
VNCRL
VNCRR

Volume of the whole brain region
Volume of the whole tumor region
Volume of the whole tumor region in the left volume
Volume of the whole tumor region in the right volume
Volume of the brain region in the left volume
Volume of the brain region in the right volume
Volume of the ED tumor region in the left volume
Volume of the ED tumor region in the right volume
Volume of the ET tumor region in the left volume
Volume of the ET tumor region in the right volume
Volume of the NCR tumor region in the left volume
Volume of the NCR tumor region in the right volume

Table A2. Volumetric features extracted from mid-coronal plane approach.
Feature Type

Description

Vwb
Vwt
VtA
VtP
VbA
VbP
VEDA
VEDP
VETA
VETP
VNCRA
VNCRP

Volume of the whole brain region
Volume of the whole tumor region
Volume of the whole tumor region in the anterior volume
Volume of the whole tumor region in the posterior volume
Volume of the brain region in the anterior volume
Volume of the brain region in the posterior volume
Volume of the ED tumor region in the anterior volume
Volume of the ED tumor region in the posterior volume
Volume of the ET tumor region in the anterior volume
Volume of the ET tumor region in the posterior volume
Volume of the NCR tumor region in the anterior volume
Volume of the NCR tumor region in the posterior volume
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Table A3. Volumetric features extracted from mid-horizontal plane approach.
Feature Type

Description

Vwb
Vwt
VtS
VtI
VbS
VbI
VEDS
VEDI
VETS
VETI
VNCRS
VNCRI

Volume of the whole brain region
Volume of the whole tumor region
Volume of the whole tumor region in the superior volume
Volume of the whole tumor region in the inferior volume
Volume of the brain region in the superior volume
Volume of the brain region in the inferior volume
Volume of the ED tumor region in the superior volume
Volume of the ED tumor region in the inferior volume
Volume of the ET tumor region in the superior volume
Volume of the ET tumor region in the inferior volume
Volume of the NCR tumor region in the superior volume
Volume of the NCR tumor region in the inferior volume
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